Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $158
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Quest Diagnostics (NYSE:DGX) while raising the price target from $150 to $158.

July 15, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained a Hold rating on Quest Diagnostics (NYSE:DGX) and raised the price target from $150 to $158.
The raised price target from $150 to $158 indicates a positive outlook from Truist Securities, which could lead to a short-term increase in DGX's stock price. However, the Hold rating suggests that the stock may not outperform the market significantly.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100